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ABSTRACT 
Diabetic foot ulcers (DFUs) are a fairly common complication of diabetes. There are two forms: neuropathic 
ulcers and ischemic ulcers, although most DFUs are a mixture of both. Neuropathic Diabetic Foot Ulcers may 
come about because high blood sugar levels damage the nerves in your legs (called peripheral neuropathy). 
This means you are less likely to feel when you have injured your foot. The injury may be something as small 
and insignificant as a blister or a cut from walking with a stone in your shoe. If you can’t feel the pain, then 
you do not know the injury is there and won’t protect it and avoid walking on it. This makes it hard for the 
wound to heal. People with diabetes often suffer from poor blood circulation, especially to the legs (as part of 
a wider circulation problem called peripheral vascular disease). This means that it takes longer for your foot 
wounds to heal than for people with normal blood flow. This is Ischemic Diabetic Foot Ulcer. If a wound 
cannot heal, it is called an ulcer and it can become very serious. A diabetic foot ulcer presents a perfect way 
for germs and infection to enter your body. Infection can spread via the blood stream and enter into your 
bones. When this happens, the best, although drastic, action is to amputate the affected limb to stop 
gangrene spreading throughout your body. In the US and the UK, around half of all amputations are related 
to diabetes. Around half of people who have a leg amputated due to diabetes die within 5 years of the 
operation. This wouldn’t need to happen if we had better foot care. Diabetic foot ulcer is one of the long 
standing complications of diabetic mellitus with the life time risk up to 25%. Many of the etiological factors 
contributing to the formation of diabetic foot ulceration may be identified using simple, inexpensive 
equipment in a clinical setting. Appropriate wound care for diabetic patients addresses these issues and 
provides optimal local ulcer therapy with debridement of necrotic tissue and provision of a moist wound-
healing environment. The pathogenesis of foot ulceration is complex, clinical presentation variable, and 
management requires early expert assessment. Interventions should be directed at infection, peripheral 
ischemia and abnormal pressure loading caused by peripheral neuropathy and limited joint mobility. 
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INTRODUCTION
 Diabetes, considered as a disease of developed 
countries, is one of the endocrine disorders that reached 
epidemic proportions worldwide[1]. The metabolic 
deregulation associated with diabetes mellitus (DM) 
cause’s secondary pathophysiologic changes in multiple 
organ systems that impose a tremendous burden on the 
individual with diabetes and on the health care system 
[2]. Lots of complications are associated with DM. Those 
complications arise chiefly from the disruption of the 
vascular system which can result in inadequate 
circulation to the peripheral body. This places the foot at 
higher risk of ulceration and infection [3]. As the 
incidence of diabetes mellitus is increasing globally, 
increase in complications is also unquestionable. Overall 
all 15% of individuals with diabetes mellitus will have 
foot ulcer during their lifetime and the 
annual incidence is 2-3% [4,5]. Diabetic foot ulcer is 
becoming major concern of diabetic patients and those 
who treat them from quality of life, social and economic 
stand point [6]. 
 According to the 2005 international diabetic 
federation report 85%of diabetes-related lower 
extremity amputations are preceded by a foot ulcer. In 
developed countries one in every six people with 
diabetes will have an ulcer during their lifetime and even 
worst in developing. The annual incidence of diabetic 
foot ulcers is ~ 3%, and the reported incidence in U.S. 
and U.K. studies ranges as high as 10%.[7] 
 
Figure 1: Areas affected by foot ulcer in a diabetic patient[3]
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BACKGROUND 
 Diabetic foot ulcers, as shown in the image 
below, occur as a result of various factors, such as 
mechanical changes in conformation of the bony 
architecture of the foot, peripheral neuropathy, and 
atherosclerotic peripheral arterial disease, all of which 
occur with higher frequency and intensity in the diabetic 
population. 
 Diabetic foot lesions are responsible for more 
hospitalizations than any other complication of diabetes. 
Diabetes is the leading cause of nontraumatic lower 
extremity amputations in the United States, with 
approximately 5% of diabetics developing foot ulcers 
each year and 1% requiring amputation. 
 Physical examination of the extremity having a 
diabetic ulcer can be divided into examination of the 
ulcer and the general condition of the extremity, 
assessment of the possibility of vascular insufficiency,[1] 
and assessment for the possibility of peripheral 
neuropathy. 
 The staging of diabetic foot wounds is based on 
the depth of soft tissue and osseous involvement.[2, 3, 4]  A 
complete blood cell count should be done, along with 
assessment of serum glucose, glycohemoglobin, and 
creatinine levels. 
 A vascular surgeon and/or podiatric surgeon 
should evaluate all patients with diabetic foot ulcers so 
as to determine the need for debridement, revisional 
surgery on bony architecture, vascular reconstruction, or 
soft tissue coverage. 
 Cilostazol is contraindicated in patients with 
congestive heart failure. See Medication regarding the 
product's black box warning. 
ETIOLOGY OF DIABETIC FOOT PROBLEMS 
 The main underlying risk factors for foot ulcers 
in diabetic patients are peripheral neuropathy and 
ischemia. 
Neuropathy 
 Epidemiologic studies have found apoint 
prevalence of distal lower limb neuropathy ranging from 
30% to 50% of the diabetic population studied.[11,12] Both 
type 1 and type 2 diabetic patients are similarly affected. 
With such frequent occurrence of neuropathy, it is no 
surprise that more than 60% of diabetic patients’ foot 
ulcers are primarily due to underlying neuropathy.[13] 
 The distal neuropathy of diabetes affects all 
components of the nervous system: sensory, motor, and 
autonomic, each of which contributes to foot ulcer 
development. Loss of nerve function correlates with 
chronic hyperglycemia, as reflected in the mean level of 
glycosylated hemoglobin over time.[14] Ischemia of the 
endoneurial microvascular circulation induced by 
metabolic abnormalities from hyperglycemia is believed 
to be the underlying mechanism for nerve 
deterioration.[15,16] 
 Neuropathy in diabetic patients is manifested in 
the motor, autonomic, and sensory components of the 
nervous system. Damage to the innervations of the 
intrinsic foot muscles leads to an imbalance between 
flexion and extension of the affected foot. This produces 
anatomic foot deformities that create abnormal bony 
prominences and pressure points, which gradually cause 
skin breakdown and ulceration. Autonomic neuropathy 
leads to a diminution in sweat and oil gland functionality. 
As a result, the foot loses its natural ability to moisturize 
the overlying skin and becomes dry and increasingly 
susceptible to tears and the subsequent development of 
infection. The loss of sensation as a part of peripheral 
neuropathy exacerbates the development of ulcerations. 
As trauma occurs at the affected site, patients are often 
unable to detect the insult to their lower extremities. As a 
result, many wounds go unnoticed and progressively 
worsen as the affected area is continuously subjected to 
repetitive pressure and shear forces from ambulation 
and weight bearing.[17] 
 
Figure 2: Common foot deformities resulting from diabetes complications: A) Claw toe deformity (increased pressure 
is placed on the dorsal and plantar aspects of the deformity as indicated by the arrow); and B) Cavus deformity (the 
rocker-bottom deformity leads to increased pressure on the plantar midfoot). [13] 
Assessment of Diabetic Foot Ulcers 
 A task force of the Foot Care Interest Group of 
the American Diabetes Association (ADA) released a 
2008 report that specifies recommended components of 
foot examinations for patients with 
diabetes.[12] Providers should take a history that takes 
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into consideration previous ulceration or amputation. 
The history should also include any neuropathic 
symptoms or symptoms that are suggestive of peripheral 
vascular disease. Further, providers should inquire about 
other complications of diabetes, including vision 
impairment suggestive of retinopathy and nephropathy, 
especially dialysis or renal transplantation. Finally, 
patients should be questioned regarding smoking 
because smoking is linked to the development of 
neuropathic and vascular disease. A complete history 
will aid in assessing the risk for foot ulceration.[13] 
 In examining the foot, visual inspection of the 
bare foot should be performed in a well-lit room. The 
examination should include an assessment of the shoes; 
inappropriate footwear can be a contributing factor to 
the development of foot ulceration. In the visual 
inspection of the foot, the evaluator should check 
between the toes for the presence of ulceration or signs 
of infection. The presence of callus or nail abnormalities 
should be noted. Additionally, a temperature difference 
between feet is suggestive of vascular disease. 
 The foot should also be examined for 
deformities. The imbalance in the innervations of the foot 
muscles from neuropathic damage can lead to the 
development of common deformities seen in affected 
patients. Hyperextension of the metatarsal-phalangeal 
joint with inter phalangeal or distal phalangeal joint 
flexion leads to hammer toe and claw toe deformities, 
respectively. The Charcot arthropathy is another 
commonly mentioned deformity found in some affected 
diabetic patients. It is the result of a combination of 
motor, autonomic, and sensory neuropathies in which 
there is muscle and joint laxity that lead to changes in the 
arches of the foot. Further, the autonomic denervation 
leads to bone demineralization via the impairment of 
vascular smooth muscle, which leads to an increase in 
blood flow to the bone with a consequential osteolysis. 
An illustration of some commonly described 
abnormalities is shown in Figure 2. 
Pathophysiology 
 Atherosclerosis and peripheral neuropathy 
occur with increased frequency in persons with diabetes 
mellitus (DM). 
Diabetes-related atherosclerosis 
 Overall, people with diabetes mellitus (DM) have 
a higher incidence of atherosclerosis, thickening of 
capillary basement membranes, arteriolar hyalinosis, 
and endothelial proliferation. Calcification and 
thickening of the arterial media (Mönckeberg sclerosis) 
are also noted with higher frequency in the diabetic 
population, although whether these factors have any 
impact on the circulatory status is unclear. 
 Diabetic persons, like people who are not 
diabetic, may develop atherosclerotic disease of large-
sized and medium-sized arteries, such as aortoiliac and 
femoropopliteal atherosclerosis. However, significant 
atherosclerotic disease of the infrapopliteal segments is 
particularly common in the diabetic population. 
Underlying digital artery disease, when compounded by 
an infected ulcer in close proximity, may result in 
complete loss of digital collaterals and precipitate 
gangrene. The reason for the prevalence of this form of 
arterial disease in diabetic persons is thought to result 
from a number of metabolic abnormalities, including 
high low-density lipoprotein (LDL) and very-low-density 
lipoprotein (VLDL) levels, inhibition of prostacyclin 
synthesis, elevated plasma fibrinogen levels, and 
increased platelet adhesiveness. 
EPIDEMIOLOGY 
 According to the National Institute of Diabetes 
and Digestive and Kidney Diseases, an estimated 16 
million Americans are known to have diabetes, and 
millions more are considered to be at risk for developing 
the disease. Diabetic foot lesions are responsible for 
more hospitalizations than any other complication of 
diabetes. Among patients with diabetes, 15% develop a 
foot ulcer, and 12-24% of individuals with a foot ulcer 
require amputation. Indeed, diabetes is the leading cause 
of nontraumatic lower extremity amputations in the 
United States. In fact, every year approximately 5% of 
diabetics develop foot ulcers and 1% require amputation. 
Age distribution for diabetic ulcers 
 Diabetes occurs in 3-6% of Americans. Of these, 
10% have type 1 diabetes and are usually diagnosed 
when they are younger than 40 years. Among Medicare-
aged adults, the prevalence of diabetes is about 10% (of 
these, 90% have type 2 diabetes). Diabetic neuropathy 
tends to occur about 10 years after the onset of diabetes, 
and, therefore, diabetic foot deformity and ulceration 
occur sometime thereafter. 
Prevalence of diabetic ulcers by race 
 The issue of diabetic foot disease is of particular 
concern in the Latino communities of the Eastern United 
States, in African Americans,[10] and in Native Americans, 
who tend to have the highest prevalence of diabetes in 
the world. 
PROGNOSIS 
 Mortality in people with diabetes and foot ulcers 
is often the result of associated large vessel 
arteriosclerotic disease involving the coronary or renal 
arteries. 
 Limb loss is a significant risk in patients with 
diabetic foot ulcers, particularly if treatment has been 
delayed.[11] Diabetes is the predominant etiology for 
nontraumatic lower extremity amputations in the United 
States. Half of all nontraumatic amputations are a result 
of diabetic foot complications, and the 5-year risk of 
needing a contra lateral amputation is 50%.[12] 
In diabetic people with neuropathy[13] even if successful 
management results in healing of the foot ulcer, the 
recurrence rate is 66% and the amputation rate rises to 
12%. 
Patient Education 
 The risk of foot ulceration and limb amputation 
in people with diabetes is lessened by patient education 
stressing the importance of routine preventive podiatric 
care, appropriate shoes, avoidance of cigarette smoking, 
control of hyperlipidemia, and adequate glycemic 
control.  
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PHYSICAL EXAMINATION 
Physical examination of the extremity having a diabetic 
ulcer can be divided into 3 broad categories: 
 Examination of the ulcer and the general condition of 
the extremity. 
 Assessment of the possibility of vascular insufficiency.  
 Assessment for the possibility of peripheral neuro-
pathy. 
We should always remember that diabetes is a systemic 
disease. Hence, a comprehensive physical examination of 
the entire patient is also vital. 
Examination of extremity 
Diabetic ulcers tend to occur in the following areas: 
 Areas most subjected to weight bearing, such as the 
heel, plantar metatarsal head areas, the tips of the 
most prominent toes (usually the first or second), 
and the tips of hammer toes (ulcers also occur over 
the malleoli because these areas commonly are 
subjected to trauma). 
 Areas most subjected to stress, such as the dorsal 
portion of hammer toes Other physical findings 
include the following: 
 Hypertrophic calluses 
 Brittle nails 
 Hammer toes 
 Fissures 
Assessment of possible peripheral arterial 
insufficiency 
 Physical examination discloses absent or 
diminished peripheral pulses below a certain level. 
 Although diminished common femoral artery 
pulsation is characteristic of aortoiliac disease, 
infrainguinal disease alone is characterized by normal 
femoral pulses at the level of the inguinal ligament and 
diminished or absent pulses distally. Specifically, loss of 
the femoral pulse just below the inguinal ligament occurs 
with a proximal superficial femoral artery occlusion. Loss 
of the popliteal artery pulse suggests superficial femoral 
artery occlusion, typically in the adductor canal. 
 Loss of pedal pulses is characteristic of disease 
of the distal popliteal artery or its trifurcation. However, 
be aware that absence of the dorsalis pedis pulse may be 
a normal anatomic variant that is noted in about 10% of 
the pediatric population. On the other hand, the posterior 
tibial pulse is present in 99.8% of persons aged 0-19 
years. Hence, absence of both pedal pulses is a more 
specific indicator of peripheral arterial disease. 
 Other findings suggestive of atherosclerotic 
disease include a bruit heard overlying the iliac or 
femoral arteries, skin atrophy, loss of pedal hair growth, 
cyanosis of the toes, ulceration or ischemic necrosis, and 
pallor of the involved foot followed by dependent rubor 
after 1-2 minutes of elevation above heart level. 
Assessment of possible peripheral neuropathy 
 Signs of peripheral neuropathy include loss of 
vibratory and position sense, loss of deep tendon reflexes 
(especially loss of the ankle jerk), trophic ulceration, foot 
drop, muscle atrophy, and excessive callous formation, 
especially overlying pressure points such as the heel. 
 The nylon monofilament test helps diagnose the 
presence of sensory neuropathy.[14] A 10-gauge 
monofilament nylon is pressed against each specific site 
of the foot just enough to bend the wire. If the patient 
does not feel the wire at 4 or more of these 10 sites, the 
test is positive for neuropathy. General use filaments can 
be obtained from the National Institute of Diabetes and 
Digestive and Kidney Diseases, or the clinician can use 
professional Semmes-Weinstein filaments. 
 
Figure 3: Features and symptoms of Diabetic Foot Ulcer [16] 
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PRINCIPLES OF MANAGEMENT 
 The first principle is to treat any infection; the 
second is to establish whether any associated ischaemia 
is amenable to revascularisation; the third is to keep 
forces applied to the ulcerated part to a minimum; and 
the fourth is to improve the condition of the wound or 
ulcer by wound-bed preparation, topical applications, 
and removal of callus. Once the wound has healed, 
attention can be turned to the prevention of ulcer 
recurrence. 
Eradication of infection 
 The antibiotic regimen chosen should be based 
on the anticipated spectrum of infecting organisms. The 
combination of an aminopenicillin and a penicillinase 
inhibitor has the required activity, but other options 
include a quinolone plus either metronidazole or 
clindamycin.47,59 Intravenous options for soft-tissue 
infection include imipenem and gentamicin. Vancomycin, 
teicoplanin, rifampicin, or linezolid should be used for 
meticillin-resistant S aureus.[12,13] 
 The same broad-spectrum antibiotics are 
appropriate for osteomyelitis. Beta-lactams and 
quinolones are concentrated intracellularly at the site of 
infection, and clindamycin penetrates bones well. It has 
always been taught that infected bone should be 
removed, but a non-surgical approach might be 
effective.[15] The relative benefits of parenteral versus 
oral antibiotics are not known, but the parenteral route 
is preferred if the foot is severely ischaemic or in cases of 
systemic illness. Nor is the optimum duration of 
treatment known, though most clinicians opt for 
prolonged courses despite risks of inducing antibiotic 
resistance.[17] 
Remediable macrovascular disease 
 Clinical evidence and positive non-invasive tests 
for macrovascular disease, such as an ankle/brachial 
pressure index below 0·8, toe systolic pressure of less 
than30 mm Hg, reduced transcutaneous oxygen tension, 
and abnormal duplex waveform on ultrasonography, 
indicate the need for assessment by a vascular surgical 
team. Options for revascularisation include angioplasty, 
thrombolysis, and bypass surgery. Distal bypass to the 
pedal vessels is increasingly common,[8,9] though with 
regional variations. Despite a huge increase in 
revascularisation procedures in the past 20 years, the 
effect on the rate of major amputation has been 
disappointing.[10] The potential benefit is clear, but the 
place of revascularisation has yet to be precisely defined. 
PREVENTION 
 Primary prevention is the aim of diabetes 
management, but secondary prevention is the goal of 
good foot-ulcer care. The recurrence rate is high13 and 
ulcer healing should be followed by a well coordinated 
programme of secondary prevention. Sadly, this 
approach is beyond the capacity of health services in 
most countries. Surgery to correct deformities and 
abnormalities of posture, gait, andload-bearing74 (eg, 
lengthening the achilles tendon) has aplace in both 
primary and secondary prevention, but isprobably 
underused. 
Primary prevention 
 Improved blood-glucose control will reduce 
microvascular complications, and reduction in 
cardiovascular risk factors will render the foot less 
susceptible to ischaemia from macrovascular disease. 
Routine surveillance will detect patients whose feet are 
at risk, and they should receive targeted care. Modelling 
indicates that this approach would be cost effective,[10] 
but primary prevention programmes have not always 
been beneficial.[13] The case for primary prevention 
might seem self-evident, but is not yet evidence based. 
 
Secondary prevention 
 A previous lesion is strongly predictive for new 
ulceration.[7] Efforts should be made to reduce abnormal 
pressure loading, 74 which might involve cushioning in 
frail and immobile people and individually fitted 
footwear in those who are mobile, but such interventions 
need to be properly targeted.[11]Education should focus 
on foot care, regular podiatry, self-examination, and 
provision of emergency contacts. Education improves 
knowledge and illness-related behaviour,[12] and led in 
one trial to a three-fold reduction in re-ulceration and 
amputation within 13 months,[13] whereas McCabe and 
colleagues showed reduction in amputation but not in 
new ulceration. These findings require confirmation.[15] 
Educational effort might be more effective if aimed 
mainly at professionals. 
CARE STRUCTURE 
 Successful management of diabetic foot ulcers 
requires close collaboration between many different 
groups in primary care and in the hospital service, and 
this collaboration might not be easy to establish while 
traditional barriers between health-care professionals 
remain in place. Supervision is also made difficult by the 
frequent coincidence of both social and medical 
problems, when the patient may be looked after by 
independent teams of professional carers. The needs and 
wishes of the patient (or his or her family) in influencing 
management choices are critical, and informed decisions 
by the patient should be an essential part of the process. 
Patients and carers should be counselled by trained 
health-care professionals at every stage, and should have 
ready access to a second opinion. The four-fold regional 
variation in incidence of major amputation reported both 
in the Netherlands and in the UK [14,15] suggests that 
patients are not always as informed and influential as 
they should be. 
CONCLUSION 
 Foot ulceration is a common complication of 
diabetes that has potentially disastrous consequences for 
patients. Fortunately, better control of blood sugar levels, 
early recognition of complications of peripheral 
neuropathy and ischemia, and using a multidisciplinary 
approach to therapy when an ulcer develops can 
dramatically reduce this problem. Primary care 
physicians are key players in this approach when they 
identify diabetic patients at risk for ulceration and the 
ninitiate appropriate early management plans. 
Investment is urgently needed for basic research into the 
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pathophysiology of chronic wounds. Clinical 
management lacks a scientific basis and is determined by 
personal preference and the availability of local expertise 
and facilities. Therefore, clinicians should identify 
differences between centres, and undertake robust 
clinical trials of management, using appropriate end 
points. Speedy and effective care will be possible only 
with effective communication and collaboration between 
all relevant professionals. Many foot-care teams are 
described as multidisciplinary, but might still be 
restricted by traditional working practices. 
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